TT30 selectively inhibits CAP activity in vivo and is bioavailable after SC injection in cynomolgous monkeys, with longer duration of activity. (A) Plasma TT30 concentrations, (B) serum CAP activity, and (C) relationship of plasma TT30 concentrations to serum CAP activity independent of time, in cynomolgous monkeys after a single TT30 dose of 20 mg/kg IV bolus injection. A single SC compared with intravenous injection of TT30 provides 3-fold longer duration of inhibition of CAP activity (24 vs 8 hours, respectively). As plasma TT30 concentrations declined, serum CAP activity increased, returning to baseline values by 72-96 hours. Results are presented through 120 hours after dosing. (D) CAP- and CCP-mediated MAC formation after IV bolus TT30 administration of 15, 30, or 60 mg/kg TT30. Each dosing group consisted of 5 male and 5 female cynomolgous monkeys. Serum samples were assayed for CAP activity. Results (% of baseline [%BL]) are presented through 48 hours after dosing.